CN106606504A - Garden burnet root sapogenin hydroxypropyl [beta]-cyclodextrin clathrate and preparation method and application thereof - Google Patents
Garden burnet root sapogenin hydroxypropyl [beta]-cyclodextrin clathrate and preparation method and application thereof Download PDFInfo
- Publication number
- CN106606504A CN106606504A CN201610893458.3A CN201610893458A CN106606504A CN 106606504 A CN106606504 A CN 106606504A CN 201610893458 A CN201610893458 A CN 201610893458A CN 106606504 A CN106606504 A CN 106606504A
- Authority
- CN
- China
- Prior art keywords
- sanguisorbigenin
- cyclodextrin
- inclusion compound
- hydroxypropylβ
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a garden burnet root sapogenin hydroxypropyl [beta]-cyclodextrin clathrate, which is made from the following raw materials, according to a weight ratio, with addition of a pharmaceutically-acceptable solvent, 0.5-10 parts of garden burnet root sapogenin and 1-20 parts of hydroxypropyl [beta]-cyclodextrin. The invention further provides a preparation method and application of the clathrate. The prepared clathrate can effectively increase hemocytes, and has remarkable significance of new dosage form development and clinical application of garden burnet root sapogenin.
Description
Technical field
The present invention relates to a kind of sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound and its production and use, belongs to medicine
Thing field.
Background technology
Bone marrow suppression is clinically common disease of hematopoietic system, and it can betide the radiation of each system tumor disease and control
Treat and (or) chemotherapy, ionising radiation cause radiation insult, virus hepatitis, piconavirus infection or medicine (chloramphenicol,
Benzene, sulfanilamide (SN), anti-insane carbuncle medicine, sedative, antithyroid drug, antidiabetic, anti-malarial, hypnotic) etc. factor.Bone marrow suppression can
Cause the damage of bone marrow microenvironment, candidate stem cell, hematopoietic cell growth factor etc., grain, red, megakaryocytic series unification system, two
It is or three is that cell is suppressed.Agranulocytosis can cause severe infections；Red blood cell is significantly reduced can cause severe anemia；Blood is little
Plate is decreased obviously and causes severe haemorrhage, even results in death.At present, clinically for bone marrow suppression, especially chemicotherapy cause
Bone marrow suppression, still lack effective treatment means, need badly and develop the preferable medicine of drug effect.
Sanguisorbigenin is from rose family garden burnet platymiscium garden burnet (Sanguisorba officinalis L.) or comes into leaves
One kind activity for obtaining is extracted in the root of garden burnet [S.officinalis L.var.longifolia (Bertol.) Yu et Li]
Composition, is the aglycon of sanguisorbin I and sanguisorbin II, chemical name：3 β, the alkene -28- carboxylic acids of 19 Alpha-hydroxy ursol -12, its structure
Formula is as follows：
Have not yet to see by active component of sanguisorbigenin and prepare cyclodextrin inclusion compound, for treating and/or preventing bone
The open report that marrow suppresses.
The content of the invention
The technical scheme is that there is provided a kind of sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound and its preparation side
Method and purposes.
The invention provides a kind of sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound, it is by the original of following weight proportioning
Material is prepared from plus pharmaceutically acceptable solvent：
Sanguisorbigenin 0.5-10 parts, hydroxypropylβ-cyclodextrin 1-20 parts.
Hydroxypropylβ-cyclodextrin：H-β-CD.
Wherein, it is prepared from plus pharmaceutically acceptable solvent by the raw material of following weight proportioning：
1 part of sanguisorbigenin, hydroxypropylβ-cyclodextrin 1-30 parts.
Wherein：It is prepared from plus pharmaceutically acceptable solvent by the raw material of following weight proportioning：
2.5 parts of sanguisorbigenin, 10 parts of hydroxypropylβ-cyclodextrin；
Or 1 part of sanguisorbigenin, 10 parts of hydroxypropylβ-cyclodextrin.
Wherein, the pharmaceutically acceptable solvent is at least one of absolute ethyl alcohol, n-butanol, ether.
Present invention also offers the method for preparing above-mentioned inclusion compound, comprises the steps：
A. sanguisorbigenin is taken by proportioning, adds pharmaceutically acceptable solvent, dissolving to obtain solution 1；
B. hydroxypropylβ-cyclodextrin is taken by proportioning, adds pharmaceutically acceptable solvent, dissolving to obtain solution 2；
C. solution 1 is added thereto in agitating solution 2, after all adding, is stirred, is evaporated, is ground, obtain final product inclusion compound.
Wherein, in step a and/or b, the pharmaceutically acceptable solvent be in absolute ethyl alcohol, n-butanol, ether at least
It is a kind of；
In step c, the time of stirring is 4h, and the temperature being evaporated is 60 DEG C.
Present invention also offers purposes of the above-mentioned inclusion compound in the medicine for preparing treatment and/or prevention bone marrow suppression.
Wherein, described medicine is the medicine for treating and/or preventing bone marrow suppression caused by chemical substance.
Present invention also offers above-mentioned inclusion compound is little in preparation rising PBL, neutrophil leucocyte, red blood cell, blood
Purposes in plate, hemoglobin, marrow hemopoietic stem cells in the medicine of the quantity of one or more.
Present invention also offers a kind of sanguisorbigenin preparation, it is by sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound
For active component, the preparation for adding pharmaceutically acceptable auxiliary material or complementary composition to be prepared from.
Wherein, described preparation is powder, tablet, pill, granule, powder-injection, injection or capsule.
Sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound prepared by the present invention, is remarkably improved drug solubility and dissolution
Degree, significantly improves the number of PBL, neutrophil leucocyte, red blood cell, blood platelet, hemoglobin and marrow hemopoietic stem cells
Amount, with significantly treatment and/or prevents the effect of bone marrow suppression, has to the clinical practice of sanguisorbigenin highly important
Meaning.
Obviously, the above of the invention, according to the ordinary technical knowledge and customary means of this area, without departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification of other various ways can also be made, is replaced or is changed.
By the following examples the specific embodiment of form, remakes further specifically to the above of the present invention
It is bright.But this scope for being interpreted as above-mentioned theme of the invention should not be only limitted to Examples below.It is all based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Description of the drawings
The each experimental mice marrow hemopoietic stem cells of Fig. 1 are counted and compared
Specific embodiment
Raw material, equipment used in the specific embodiment of the invention is known product, is obtained by buying commercially available prod.
The preparation of the inclusion compound of the present invention of embodiment 1
Raw material is weighed by following proportionings：
Sanguisorbigenin 0.5g, hydroxypropylβ-cyclodextrin 1.5g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 50ml obtains solution 1 to dissolving.It is another by proportioning take H- β-
CD, adds the absolute ethyl alcohol ultrasound of 15ml to dissolving, and obtains solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while
Solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allows its mixed liquor to stir in constant temperature magnetic force
Mix and stirred four hours on device.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be obtained final product
To inclusion compound.
The preparation of the inclusion compound of the present invention of embodiment 2
Raw material is weighed by following proportionings：
Sanguisorbigenin 1.5g, hydroxypropylβ-cyclodextrin 5g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 150ml obtains solution 1 to dissolving.It is another by proportioning take H- β-
CD, adds the absolute ethyl alcohol ultrasound of 50ml to dissolving, and obtains solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while
Solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allows its mixed liquor to stir in constant temperature magnetic force
Mix and stirred four hours on device.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be obtained final product
To inclusion compound.
The preparation of the inclusion compound of the present invention of embodiment 3
Raw material is weighed by following proportionings：
Sanguisorbigenin 2.5g, hydroxypropylβ-cyclodextrin 10g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 250ml obtains solution 1 to dissolving.It is another by proportioning take H- β-
CD, adds the absolute ethyl alcohol ultrasound of 100ml to dissolving, and obtains solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while
Solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allows its mixed liquor to stir in constant temperature magnetic force
Mix and stirred four hours on device.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be obtained final product
To inclusion compound.
The preparation of the inclusion compound of the present invention of embodiment 4
Raw material is weighed by following proportionings：
Sanguisorbigenin 4.5g, hydroxypropylβ-cyclodextrin 45g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 450ml obtains solution 1 to dissolving.It is another by proportioning take H- β-
CD, adds the absolute ethyl alcohol ultrasound of 450ml to dissolving, and obtains solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while
Solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allows its mixed liquor to stir in constant temperature magnetic force
Mix and stirred four hours on device.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be obtained final product
To inclusion compound.
The preparation of the inclusion compound of the present invention of embodiment 5
Raw material is weighed by following proportionings：
Sanguisorbigenin 6.5g, hydroxypropylβ-cyclodextrin 16.5g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 650ml obtains solution 1 to dissolving.It is another by proportioning take H- β-
CD, adds the absolute ethyl alcohol ultrasound of 165ml to dissolving, and obtains solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while
Solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allows its mixed liquor to stir in constant temperature magnetic force
Mix and stirred four hours on device.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be obtained final product
To inclusion compound.
The preparation of the inclusion compound of the present invention of embodiment 6
Raw material is weighed by following proportionings：
Sanguisorbigenin 8.5g, hydroxypropylβ-cyclodextrin 35g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 850ml obtains solution 1 to dissolving.It is another by proportioning take H- β-
CD, adds the absolute ethyl alcohol ultrasound of 350ml to dissolving, and obtains solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while
Solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allows its mixed liquor to stir in constant temperature magnetic force
Mix and stirred four hours on device.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be obtained final product
To inclusion compound.
The preparation of the inclusion compound of the present invention of embodiment 7
Raw material is weighed by following proportionings：
Sanguisorbigenin 10g, hydroxypropylβ-cyclodextrin 45g.
Preparation method is as follows：
Sanguisorbigenin is taken by proportioning, plus the absolute ethyl alcohol ultrasound of 1000ml obtains solution 1 to dissolving.Separately take H- by proportioning
β-CD, add the absolute ethyl alcohol ultrasound of 450ml to dissolving, and obtain solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, together
When solution 1 is slowly added in solution 2 with dropper, after solution 1 all adds solution 2, allow its mixed liquor in constant temperature magnetic force
Stir four hours on agitator.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, take that to be evaporated thing finely ground i.e.
Obtain inclusion compound.
Beneficial effects of the present invention are proved below by way of specific experiment.
Experimental example 1 prepares the quality evaluation of sanguisorbin inclusion compound using different inclusion materials
According to the property of sanguisorbigenin, selection beta-schardinger dextrin, methyl beta-cyclodextrin, hydroxypropylβ-cyclodextrin are for this research
Carrier material makes sanguisorbigenin inclusion compound.
Following proportionings weigh raw material：Sanguisorbigenin 5g, inclusion material 15g.
Preparation method is as follows：
Sanguisorbigenin is weighed, plus the absolute ethyl alcohol ultrasound of 100 times of amounts obtains solution 1 to dissolving.Inclusion material is separately taken, plus
Enter the absolute ethyl alcohol ultrasound of 10 times of amounts to dissolving, obtain solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while with drop
Pipe is slowly added to solution 1 in solution 2, after solution 1 all adds solution 2, allows its mixed liquor in constant temperature blender with magnetic force
Upper stirring four hours.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be wrapped
Compound.
Survey its inclusion rate (quality of sanguisorbigenin/sanguisorbigenin dispensing quality in inclusion rate (%)=inclusion compound ×
100%), the results are shown in Table 1.
The different inclusion materials of table 1 prepare the quality evaluation of sanguisorbigenin inclusion compound
Note：Compared with beta-schardinger dextrin group, * P<0.05.
From table 1, the sanguisorbigenin hydroxypropyl beta-ring prepared using present invention inclusion material hydroxypropylβ-cyclodextrin
Cyclodextrin inclusion compound, inclusion rate is high, and inclusion effect is good.And use inclusion compound inclusion rate prepared by other inclusion materials poor.
As a result show, only the sanguisorbigenin hydroxypropyl beta prepared using present invention inclusion material hydroxypropylβ-cyclodextrin-
Cyclodextrin encapsulated amount of substance is optimal.
Experimental example 2 prepares sanguisorbigenin hydroxypropylβ-cyclodextrin bag using not same amount hydroxypropylβ-cyclodextrin carrier material
The quality evaluation of compound
Sanguisorbigenin, the hydroxypropylβ-cyclodextrin of different proportion are weighed respectively, are tested as follows：Take a certain amount of
Sanguisorbigenin, plus the absolute ethyl alcohol ultrasound extremely dissolving of 100 times of amounts, obtain solution 1.Separately hydroxypropylβ-cyclodextrin is taken by proportioning, plus
Enter the absolute ethyl alcohol ultrasound of 10 times of amounts to dissolving, obtain solution 2.Solution 2 is placed in constant temperature blender with magnetic force and is stirred, while with drop
Pipe is slowly added to solution 1 in solution 2, after solution 1 all adds solution 2, allows its mixed liquor in constant temperature blender with magnetic force
Upper stirring four hours.Mixed liquor is poured in evaporating dish, is placed on 60 DEG C of water-baths, be evaporated, taken and be evaporated that thing is finely ground to be wrapped
Compound, surveys its inclusion rate.The results are shown in Table 2.
Same amount hydroxypropylβ-cyclodextrin carrier material does not prepare the bag of sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound to table 2
Conjunction rate
Note：With 1:0.5 group is compared, * P<0.05.
From table 2, only sanguisorbigenin of the present invention is being adopted：Can just obtain ground in hydroxypropylβ-cyclodextrin proportion
Elm sapogenin hydroxypropylβ-cyclodextrin inclusion compound；Wherein, using sanguisorbigenin：Hydroxypropylβ-cyclodextrin is 1:1-1:20 scopes
Interior, inclusion rate reaches more than 90%, is 1 with hydroxypropylβ-cyclodextrin:0.5 compares, significant difference (P<0.05), hydroxypropyl is shown
Beta-schardinger dextrin is good to sanguisorbigenin inclusion effect.
The sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound pharmacodynamic study of the present invention of experimental example 3
1. experiment material
1.1 test medicine：Sanguisorbigenin-H- beta-CD inclusions (preparing according to embodiment 1～7), sanguisorbigenin, ring
Phosphamide.
1.2 animal used as test：KM- mouse：18.5～22.5g.
1.3 laboratory apparatus：Full-automatic blood cell analysis machine；BS-600L electronic balances：Specification：600g/0.1g, Shanghai friend's sound
Weighing apparatus Co., Ltd.
1.4 statistical method
Statistical analysis is carried out with the softwares of SPSS 17.0.Data are with mean ± standard deviationRepresent, Dan Yin is adopted between group
Plain variance analysis, carries out LSD inspections between the neat person's group of variance, heterogeneity of variance person carries out Tamhane ' s T2 inspections.
2. experimental technique
2.1 animals used as test are grouped and prepared by model
All Animal adaptabilities are randomly divided into after feeding 1 week by body weight：Blank group；Model group；Sanguisorbigenin-H- β-CD
Inclusion compound group, prepares according to embodiment 1～7, is configured to 2.5mgkg-1Suspension, is respectively set to 1～7 group of sample, garden burnet
Saponin(e tuple；10%DMSO- physiological saline solutions are used, 2.5mgkg is configured to-1Suspension.Test the 1st day, in addition to blank group,
Remaining each group mouse presses 50mgkg-1Dosage intraperitoneal injection of cyclophosphamide normal saline solution, for three days on end, naive mice tail
Intravenous injection equal-volume physiological saline.
2.2 administration
Each experimental group from test the 1st day start according to dosage, administering mode give relative medicine, blank group and model group mouse
Gastric infusion equal-volume physiological saline, continuous 7 days.
2.3 collection of specimens
Test the 8th day, each experimental mice eye socket takes blood, collect to be measured with the 0.5mlEP pipes equipped with EDTA anti-coagulants.
2.4 Testing index and method
Peripheral hemogram is detected：Using full-automatic blood counting instrument to each experimental mice PBL (WBC), neutrality
Granulocyte (NEUT) red blood cell (RBC), blood platelet (PLT), hemoglobin (HGB) are counted.
Marrow hemopoietic stem cells are counted
0.2% PBS goes out right side of mice femur bone marrow cell, takes out 106 cell centrifugations, abandons supernatant, is adding 30 μ L just
Often mice serum adds the rat anti-mouse CD34+ antibody of 10 μ L FITC marks, control to close unspecific binding sites
Pipe adds the corresponding control antibodies of 10 μ L, 4 DEG C of lucifuges to react 30min.2mL erythrocyte cracked liquids are added, 5min is acted on, cell 2 is washed
It is secondary, the PI dye liquors of final concentration of 3 μ g/mL are added, using flow cytomery bone marrow cell CD34+ antigen presentations.
3. experimental result
3.1 peripheral blood major blood cells are counted and compared, and are shown in Table 3-4.
The each experimental mice peripheral blood haemocyte quantity of table 3
Note：Compare with model group, * P<0.05, * * P<0.01；Note：Compare with sanguisorbin tuple,△P<0.05,△△P
<0.01。
From table 3, compare with model group, there was no significant difference for sanguisorbin tuple, sanguisorbigenin-H- β-cdinclusions
Thing group mouse peripheral blood WBC, RBC, PLT quantity has significantly raise (P<0.05)；Compare with sanguisorbin tuple, sanguisorbin
Unit-H- beta-CD inclusion group mouse peripheral blood WBC, RBC, PLT quantity has significantly raise (P<0.05).Wherein 3 groups of tools of sample
There is extremely notable rising (P<0.01).
The each experimental mice peripheral blood haemocyte quantity of table 4
Note：Compare with model group, * P<0.05, * * P<0.01；Note：Compare with sanguisorbin tuple,△P<0.05,△△P
<0.01。
From table 4, compare with model group, there was no significant difference for sanguisorbin tuple, sanguisorbigenin-H- β-cdinclusions
Thing group mouse peripheral blood NEUT and HGB quantity has significantly raise (P<0.05)；Compare with sanguisorbin tuple, sanguisorbin
Unit-H- beta-CD inclusion group mouse peripheral blood NEUT and HGB quantity has significantly raise (P<0.05).Wherein 3 groups of sample has
Extremely significantly raise (P<0.01).
3.2 marrow hemopoietic stem cells are counted and compared
See Fig. 1.
From fig. 1, it can be seen that comparing with model group, sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound group mouse hemopoietic of the present invention
Stem cell population has significantly raise (P<0.05), there was no significant difference for sanguisorbin tuple；Compare with sanguisorbin tuple, this
Invention sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound group mouse hematopoietic stem cell quantity has significantly raise (P<0.05).
Above test result indicate that, it is thin that sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound of the present invention can effectively raise blood
Born of the same parents, and directly with sanguisorbigenin active compound to no effect.
To sum up, the sanguisorbigenin inclusion compound that prepared by the present invention efficiently solves the problems, such as that sanguisorbigenin solubility is low,
Improve sanguisorbigenin bioavilability, can effective hemocytes increasing, bone marrow suppression is effectively prevented and treated, to sanguisorbigenin
Clinical practice tool is of great significance.
Claims (10)
1. a kind of sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound, it is characterised in that：It is by the raw material of following weight proportioning
It is prepared from plus pharmaceutically acceptable solvent：
Sanguisorbigenin 0.5-10 parts, hydroxypropylβ-cyclodextrin 1-20 parts.
2. inclusion compound according to claim 1, it is characterised in that：It is plus pharmaceutically by the raw material of following weight proportioning
Acceptable solvent is prepared from：
1 part of sanguisorbigenin, hydroxypropylβ-cyclodextrin 1-30 parts.
3. inclusion compound according to claim 1 and 2, it is characterised in that：It is to add medicine-feeding by the raw material of following weight proportioning
Acceptable solvent is prepared from：
2.5 parts of sanguisorbigenin, 10 parts of hydroxypropylβ-cyclodextrin；
Or 1 part of sanguisorbigenin, 10 parts of hydroxypropylβ-cyclodextrin.
4. the inclusion compound according to claim 1-3 any one, it is characterised in that：The pharmaceutically acceptable solvent is
At least one of absolute ethyl alcohol, n-butanol, ether.
5. the method for preparing the inclusion compound described in claim 1-4 any one, it is characterised in that：Comprise the steps：
A. sanguisorbigenin is taken by proportioning, adds pharmaceutically acceptable solvent, dissolving to obtain solution 1；
B. hydroxypropylβ-cyclodextrin is taken by proportioning, adds pharmaceutically acceptable solvent, dissolving to obtain solution 2；
C. solution 1 is added thereto in agitating solution 2, after all adding, is stirred, is evaporated, is ground, obtain final product inclusion compound.
6. method according to claim 5, it is characterised in that：
In step a and/or b, the pharmaceutically acceptable solvent is at least one of absolute ethyl alcohol, n-butanol, ether；
In step c, the time of stirring is 4h, and the temperature being evaporated is 60 DEG C.
7. the inclusion compound described in claim 1-4 any one is preparing the purposes of the medicine for treating and/or preventing bone marrow suppression.
8. purposes according to claim 7, it is characterised in that：Described medicine is to treat and/or prevent chemical substance to lead
The medicine of the bone marrow suppression of cause.
9. the inclusion compound described in claim 1-4 any one raises PBL, neutrophil leucocyte, red thin preparing
Purposes in born of the same parents, blood platelet, hemoglobin, marrow hemopoietic stem cells in the medicine of the quantity of one or more.
10. a kind of sanguisorbigenin preparation, it is characterised in that：It is to live by sanguisorbigenin hydroxypropylβ-cyclodextrin inclusion compound
Property composition, the preparation for adding pharmaceutically acceptable auxiliary material or complementary composition to be prepared from.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015106743854 | 2015-10-16 | ||
| CN201510674385 | 2015-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106606504A true CN106606504A (en) | 2017-05-03 |
Family
ID=58615004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610893458.3A Pending CN106606504A (en) | 2015-10-16 | 2016-10-13 | Garden burnet root sapogenin hydroxypropyl [beta]-cyclodextrin clathrate and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106606504A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018133105A1 (en) * | 2017-01-23 | 2018-07-26 | 四川英路维特医药科技有限公司 | ZIYUGLYCOGENIN-HYDROXYPROPYL β-CYCLODEXTRIN INCLUSION COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593436A (en) * | 2003-09-08 | 2005-03-16 | 成都地奥制药集团有限公司 | Application of ursane type triterpenoid saponin in the preparing process of leucocyte and/or platelet increasing medicine |
| CN101138545A (en) * | 2006-09-08 | 2008-03-12 | 广州天安医药科技有限公司 | Clathrate compound containing ginsenoside Rg2 and method of preparing the same |
| CN103933203A (en) * | 2014-04-01 | 2014-07-23 | 陕西医大血友病研究院 | Compound haemopoietic capsule for treating aplastic anemia and preparation method thereof |
-
2016
- 2016-10-13 CN CN201610893458.3A patent/CN106606504A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593436A (en) * | 2003-09-08 | 2005-03-16 | 成都地奥制药集团有限公司 | Application of ursane type triterpenoid saponin in the preparing process of leucocyte and/or platelet increasing medicine |
| CN101138545A (en) * | 2006-09-08 | 2008-03-12 | 广州天安医药科技有限公司 | Clathrate compound containing ginsenoside Rg2 and method of preparing the same |
| CN103933203A (en) * | 2014-04-01 | 2014-07-23 | 陕西医大血友病研究院 | Compound haemopoietic capsule for treating aplastic anemia and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 高小平等: ""地榆促造血作用的有效部位筛选"", 《中国天然药物》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018133105A1 (en) * | 2017-01-23 | 2018-07-26 | 四川英路维特医药科技有限公司 | ZIYUGLYCOGENIN-HYDROXYPROPYL β-CYCLODEXTRIN INCLUSION COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dorr et al. | Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide | |
| CN101926834B (en) | Morchella conica granules and preparation method and application thereof | |
| CN106606504A (en) | Garden burnet root sapogenin hydroxypropyl [beta]-cyclodextrin clathrate and preparation method and application thereof | |
| CN108703950A (en) | A kind of emulsion injection that roller pyrrole is smooth | |
| Sinha et al. | Long-term effect of insulin on glucose transport and insulin binding in cultured adipocytes from normal and obese humans with and without non-insulin-dependent diabetes. | |
| CN106540269A (en) | Sanguisorbin II hydroxypropyl beta cyclodextrin clathrates and its production and use | |
| Wilson et al. | Natural killer cells in insulin dependent diabetes mellitus. | |
| CN106580881A (en) | Sanguisorba officinalis aglycone lipidosome, and preparation method and purpose thereof | |
| CN110200916A (en) | A kind of dual acid-sensitive liposome, using it as drug of carrier and preparation method thereof | |
| CN106580884A (en) | Garden burnet sapogenin solid dispersion as well as preparation method and application thereof | |
| CN106581692A (en) | Ziyuglycoside I inclusion compound and preparation method thereof | |
| CN102188435B (en) | Compound sulfaclozine sodium suspension and preparation method thereof | |
| CN106551906A (en) | A kind of sanguisorbin II emulsions and preparation method thereof | |
| CN106606474A (en) | 3beta, 19alpha-hydroxy-urs-12-en-28-carboxylic acid injection, and preparation method and applications thereof | |
| CN106606477A (en) | Sanguisorba aglycone emulsion for injection and preparing method and use thereof | |
| CN106551907A (en) | II liposome of a kind of sanguisorbin and preparation method thereof | |
| WO2018133105A1 (en) | ZIYUGLYCOGENIN-HYDROXYPROPYL β-CYCLODEXTRIN INCLUSION COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| WO2018133104A1 (en) | Ziyu-glycoside ii and hydroxypropyl-beta-cyclodextrin inclusion compound, preparation method therefor and use thereof | |
| CN106606478A (en) | Sanguisorba officinalis sapogenin oral emulsion as well as preparation method and applications thereof | |
| KR20050040905A (en) | Steroid conjugates, preparation thereof and the use thereof | |
| WO2018133106A1 (en) | Ziyuglycogenin solid dispersion, preparation method therefor and use thereof | |
| CN106539763A (en) | II solid dispersion of a kind of sanguisorbin and preparation method thereof | |
| CN106551899A (en) | A kind of Ziyuglycoside I I injection and its production and use | |
| WO2018133111A1 (en) | Ziyuglycogenin emulsion for injection, preparation method therefor and use thereof | |
| WO2018133108A1 (en) | Ziyuglycoside ii emulsion and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170503 |